TB-500 10mg/vial 1 Vial by Bio-Peptide

Usage

1. Remove the TB-500 vial from −20 °C storage and allow it to reach room temperature naturally for 10–15 minutes before handling — thermal shock can degrade lyophilised peptide structure.
2. Draw 1–2 mL of bacteriostatic water into a fresh insulin syringe, then insert the needle through the rubber stopper at an angle and release the water slowly down the inner vial wall to avoid foaming.
3. Swirl the vial gently between your palms for 20–30 seconds until the powder is fully dissolved — the solution should be clear and colourless; discard if particulates remain or cloudiness persists.
4. Calculate your target draw volume based on your reconstitution ratio: if 10 mg is dissolved in 2 mL bacteriostatic water, each 0.1 mL = 0.5 mg of TB-500.
5. Cleanse the subcutaneous injection site (abdomen or lateral thigh are preferred for systemic peptide delivery) with an alcohol swab and allow it to dry fully before pinching the skin and inserting the insulin syringe needle at 45°.
6. After injecting, store the reconstituted vial capped in the refrigerator at 2–8 °C, use within 28 days, and always use a new syringe for each subsequent draw to prevent contamination of the remaining solution.

Warnings

Frequently asked questions

What is TB-500 used for in research and bodybuilding contexts?

TB-500 is used to support systemic tissue regeneration, accelerate recovery from musculoskeletal injuries, and reduce chronic inflammation affecting tendons, ligaments, and muscle. Unlike peptides that act locally, TB-500's Thymosin Beta-4 fragment circulates systemically, enabling it to address multiple damaged tissue sites concurrently — making it particularly relevant for athletes managing overuse injuries or post-training structural stress.

How does TB-500 improve joint flexibility and reduce stiffness?

TB-500 improves flexibility by modulating the MMP/TIMP balance in connective tissue, which governs healthy collagen remodelling versus fibrotic stiffening. By suppressing excess fibrosis and encouraging controlled matrix turnover in tendons, joint capsules, and fasciae, Thymosin Beta-4 helps restore pliability to chronically tight or scarred connective structures — an effect observed in both animal model studies and anecdotal clinical experience with structured dosing protocols.

How do you structure a weekly TB-500 dosing protocol for systemic recovery?

A standard research-informed TB-500 protocol uses a loading phase of 2 mg administered twice per week for four to six weeks, delivering 4 mg total per week during that window. After the loading phase, a maintenance dose of 2 mg once per week for four additional weeks is commonly employed. Injections are typically subcutaneous. Total cycle duration is eight to ten weeks, after which a rest period of equivalent length is recommended before re-initiation.

How do you reconstitute and store Bio-Peptide TB-500 after opening?

Reconstitute the lyophilised TB-500 powder by injecting 1–2 mL of bacteriostatic water slowly down the inner vial wall — never shake the vial, swirl gently instead. Once reconstituted, store the vial refrigerated at 2–8 °C and use within 28 days. Unopened lyophilised vials remain stable at −20 °C for extended periods. Always use a fresh insulin syringe for each draw to avoid microbiological contamination of the remaining solution.

Can TB-500 be drawn and injected using a standard insulin syringe?

Yes — a standard U-100 insulin syringe (0.3 mL or 1 mL capacity, 28–31 gauge needle) is the recommended tool for TB-500 administration. After reconstituting with bacteriostatic water, the desired dose is drawn by volume: for example, if 2 mg is dissolved in 2 mL of bacteriostatic water, each 0.5 mL drawn delivers 0.5 mg of TB-500. The fine gauge minimises injection-site discomfort and is suitable for subcutaneous pinching-technique delivery. (2) angle_used

Manufacturer

Bio-Peptide's operational identity was shaped by a deliberate constraint written into its production workflow before the company achieved any significant market presence: no batch would be cleared for distribution until it had passed through two independently conducted laboratory tests — not internal assessments, but externally commissioned analyses with batch-specific documentation attached to every release. What that constraint looks like in practice for TB-500: an HPLC (High-Performance Liquid Chromatography) analysis contracted to a third-party laboratory, tasked with confirming that the peptide's molecular sequence matches the Thymosin Beta-4 active fragment and that the purity percentage meets the company's defined threshold. Running in parallel is a LAL (Limulus Amebocyte Lysate) endotoxin screen — the gold-standard method for detecting bacterial lipopolysaccharide contamination that could render an otherwise pure peptide unsuitable for research injection. Both verifications are performed externally and documented per batch, not per product line. This architecture — external, batch-specific, dual-checkpoint — predated Bio-Peptide's commercial growth and has remained structurally intact as the company's product range expanded across the European research-peptide market.